Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C

This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic hepatitis C who have not been previously treated with Interferon.

Study Overview

• Status: Completed
• Conditions: Chronic Hepatitis c
• Intervention / Treatment: Drug: PEG-IFN-SA /RBV; Drug: Pegasys /RBV

Detailed Description

Total 720 subjects are divided into two groups and treated separately according to the HCV genotype（genotype 2,3 and non-genotype 2,3). With 2:1 ratio between experimental group and positive-control group (Peginterferon alfa-2a (Pegasys) plus RBV), 216 subjects for genotype 2,3 and 504 subjects for non-genotype2,3 will be enrolled. Accordingly, PEG-IFN-SA once weekly and RBV twice a day (bid) are given for 24 weeks and 48 weeks respectively to the HCV genotype 2,3 and the HCV non-genotype 2,3 .

• Study Type: Interventional
• Enrollment (Actual): 719
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Peking University First Hospital
  • Beijing, China
    • Beijing Ditan Hospital, Capital Medical University
  • Beijing, China
    • Beijing Youan Hospital, Capital Medical University
  • Beijing, China
    • Peking University People's Hospital
  • Beijing, China
    • 302 Military Hospital of China
  • Beijing, China
    • Beijing Youyi Hospital, capital Medical University
  • Beijing, China
    • General Hospital of Beijing Military Region
  • Chongqing, China
    • The Second Affiliated Hospital of Chongqing Medical University
  • Chongqing, China
    • Chongqing Southwest Hospital
  • Shanghai, China
    • Shanghai Public Health Clinical Center
  • Tianjin, China
    • Tianjin Infectious Disease Hospital
  • Gansu
    • Lanzhou, Gansu, China
      • First Affiliated Hospital of Lanzhou University
  • Guangdong
    • Guangzhou, Guangdong, China
      • Guangzhou Eighth People's Hospital
    • Guangzhou, Guangdong, China
      • Nanfang Hospital Southern Medical Unbiversity
  • Guangxi
    • Nanning, Guangxi, China
      • The First Affiliated Hospital of Guangxi Medical University
  • Hebei
    • Shijiazhuang, Hebei, China
      • Third Affiliated Hospital, Hebei Medical University
  • Heilongjiang
    • Harbin, Heilongjiang, China
      • The Second Affiliated Hospital of Harbin Medical University
  • Henan
    • Xinxiang, Henan, China
      • The First Affiliated Hospital of Xinxiang Medical University
    • Zhengzhou, Henan, China
      • Henan Provincial People's Hospital
  • Hubei
    • Wuhan, Hubei, China
      • Tongji Hospital, Tongji Medical College Huazhong University of Science ＆ Technology
    • Wuhan, Hubei, China
      • Zhongnan Hospital of Wuhan University
    • Wuhan, Hubei, China
      • Union hospital, Tongji Medical College Huazhong University of Science ＆ Technology
  • Hunan
    • Changsha, Hunan, China
      • The Second Xiangya Hospital of Central South University
    • Changsha, Hunan, China
      • Xiangya Hospital Central-South University
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Jiangsu Province Hospital
    • Nanjing, Jiangsu, China
      • The Second Hospital of Nanjing
  • Jiangxi
    • Nanchang, Jiangxi, China
      • First Affiliated Hospital of Nanchang University
  • Jilin
    • Changchun, Jilin, China
      • The First Affiliated Hospital of Jilin University
    • Yanji, Jilin, China
      • Yanbian University Hospital (Yanbian Hospital)
  • Liaoning
    • Shenyang, Liaoning, China
      • The Sixth People's Hospital of Shenyang
  • Shaanxi
    • Xi'an, Shaanxi, China
      • First Affiliated Hospital Of Medical College of Xian Jiaotong University
    • Xi'an, Shaanxi, China
      • Second Affiliated Hospital Of Medical College of Xian Jiaotong University
    • Xi'an, Shaanxi, China
      • Tangdu hospital,fourth military medical university
  • Shandong
    • Jinan, Shandong, China
      • Qilu Hospital of Shandong University
    • Jinan, Shandong, China
      • Jinan Infectious Disease Hospital
    • Qingdao, Shandong, China
      • QingDao Municipal Hospital
  • Shanxi
    • Taiyuan, Shanxi, China
      • The First Hospital of Shanxi Medical University
  • Sichuan
    • Chengdu, Sichuan, China
      • West China Hospital, Sichuan University
    • Chengdu, Sichuan, China
      • Sichuan Academy of Medical Science ＆Sichuan Provincial People's Hospital
  • Xinjiang
    • Urumqi, Xinjiang, China
      • The First Teaching Hospital of Xinjiang Medical University
  • Zhejiang
    • Wenzhou, Zhejiang, China
      • The First Affiliated Hospital of Wenzhou Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 18- 65 years
• Body Mass Index (BMI) 18-30
• Chronic hepatitis C , diagnosed according to Chinese guideline of Hepatitis C (year 2004)
• Detectable serum HCV-RNA by quantitative polymerase chain reaction assay and positive anti-HCV antibody
• Female subjects of childbearing age with no history of menopause and negative pregnancy test, both female and male( including their partners ) subjects were required to conduct adequate contraception since screening until the 6 months after treatment
• Volunteered to participate in this study, understood and signed an informed consent

Exclusion Criteria:

• Previous IFN treated patients
• Hepatotoxic drugs was systematically used more than two weeks within past 6 months
• Systemic therapy with potent immunomodulatory agents such as adrenocorticotropic hormone, thymosin α1, etc more than two weeks within past 6 months, not including corticosteroid nasal sprays, inhaled steroids and / or topical steroids
• Co-infection with HAV, HBV, HEV, EBV, CMV and HIV
• Evidences of hepatic decompensation, including but not limited to serum total bilirubin> 2 times the upper limit of normal (ULN); serum albumin <35g/L; prothrombin activity (PTA) <60%; ascites, upper gastrointestinal bleeding and hepatic encephalopathy; Child-Pugh score B/C grade
• Diagnosed with primary hepatocellular carcinoma or supported by evidences including but not limited to AFP> l00ng/ml, suspicious liver nodules by imaging examinations
• Liver diseases from causes other than HCV infection, including alcoholic liver disease, non-alcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis (antinuclear antibody titer higher than 1:100), hepatolenticular degeneration (Wilson's disease) and hemochromatosis, etc.
• White blood cell count <3×109/L; Neutrophil count<1.5×109/L; platelet count<90×109/L; hemoglobin below the lower limit of normal
• Serum creatinine above the ULN
• Serum creatine kinase> 3 ULN
• Diabetes mellitus or Poorly controlled Thyroid Diseases
• Poorly controlled hypertension (systolic blood pressure> 140mmHg, or diastolic blood pressure> 90 mmHg) with hypertension -related retinal lesions
• Immunodeficiency or autoimmune diseases including but not limited to inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, scleroderma, Sjogren's syndrome, autoimmune thrombocytopenia, etc.
• Psychiatric and nervous system disorders, including history of Psychiatric illness or with family history (especially depression, depressive tendencies, epilepsy and hysteria, etc.)
• Severe cardiovascular diseases (New York Heart Association functional class (NYHA) Ⅲ level and above, myocardial infarction occurred within past 6 months or PTCA performed within past 6 months, unstable angina, uncontrolled arrhythmias)
• Serious blood disorders (all kinds of anemia, hemophilia, etc.)
• Severe kidney disease (chronic kidney disease, renal insufficiency, etc.)
• Serious digestive diseases (gastrointestinal ulcers, colitis, etc.)
• Severe respiratory disease (pneumonia, chronic obstructive pulmonary disease, interstitial lung disease, etc.)
• Retinal disease (retinal exfoliation, macular hole, retinal tumors, etc.)
• Malignancies
• Function organs transplant
• Allergies or severe allergies, especially allergic to study drugs or any ingredients of the study drugs
• Evidence of alcohol or drug abuse (average alcohol consumption male> 40g / day, female> 20g / day)
• Pregnant or lactating women
• Usage of prohibition drugs in this study
• Participated in other clinical trials 3 months prior to the screening
• Unwilling to sign the informed consent and adhere to treatment requirements
• Other conditions not suitable for study judged by investigators

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PEG-IFN-SA /RBV T1(Genotype2,3); PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks	Drug: PEG-IFN-SA /RBV
Active Comparator: Pegasys /RBV C1(Genotype 2,3); Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks	Drug: Pegasys /RBV
Experimental: PEG-IFN-SA /RBV T2(Non-genotype 2,3); PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks	Drug: PEG-IFN-SA /RBV
Active Comparator: Pegasys /RBV C2(Non-genotype 2,3); Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks	Drug: Pegasys /RBV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SVR (sustained virologic response)	defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at 24 weeks after the end of SVR (sustained virologic response) defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at 24 weeks after the end of treatment	24 weeks after 24 or 48 weeks of study therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RVR(rapid virologic response)	defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 4	weeks 4 of study therapy
cEVR (complete early virologic response)	defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 12	weeks 12 of study therapy
ETVR( end of treatment virologic response)	defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at the end of treatment	weeks 24 of study therapy for genotype 2,3, and weeks 48 of study therapy for non-genotype 2,3
eRVR ( extended rapid virologic response)	defined as the proportion of patients who had undetectable plasma HCV RNA (HCV RNA < 15 IU/mL) at weeks 4 and 12	weeks 4 and 12 of study therapy
No-responses	defined as the proportion of patients who had less than a <2 log IU/ml plasma HCV RNA decline at weeks 12 or had detectable plasma HCV RNA at weeks 24	weeks 12 or weeks 24 of study therapy
Breakthrough	defined as the proportion of patients who had detectable plasma HCV RNA at any point during treatment after virological response( undetectable plasma HCV RNA)	weeks 12, 24 of study therapy for genotype 2,3, and weeks 12, 24 and 48 of study therapy for non-genotype 2,3
Relapse	defined as the proportion of patients who had undetectable HCV RNA at the end of treatment, but reappearance of HCV RNA after the then	12 and 24 weeks after 24 or 48 weeks of study therapy

Collaborators and Investigators

• Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd.
• Investigators: Principal Investigator: Cheng jun, MD, PhD, Beijing Ditan Hospital

Study record dates

Study Major Dates

• Study Start: June 1, 2013
• Primary Completion (Actual): August 1, 2015
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: July 17, 2013
• First Submitted That Met QC Criteria: July 17, 2013
• First Posted (Estimate): July 19, 2013

Study Record Updates

• Last Update Posted (Estimate): September 25, 2015
• Last Update Submitted That Met QC Criteria: September 24, 2015
• Last Verified: September 1, 2015

More Information

Terms related to this study

• Keywords: ribavirin; interferon; sustained virological response
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis; Hepatitis A; Hepatitis C; Hepatitis, Chronic; Hepatitis C, Chronic; Anti-Infective Agents; Antiviral Agents; Peginterferon alfa-2a
• Other Study ID Numbers: KAWIN-002-2